Featured Research

from universities, journals, and other organizations

Promising Alzheimer's drug trialled in large EU study

Date:
December 9, 2013
Source:
University of Gothenburg
Summary:
An extensive European study is currently investigating whether a drug used to treat high blood pressure may also help patients with Alzheimer's disease.

An extensive European study is currently investigating whether a drug used to treat high blood pressure may also help patients with Alzheimer's disease. The EU is investing almost 6 million euros on the project, in which Sahlgrenska Academy and Sahlgrenska University Hospital are responsible for Sweden's contribution.

The drug being trialled in the study, nilvadipine, is a well-proven treatment for high blood pressure. Research has shown that nilvadipine counters the formation of amyloid plaques in animal brains.

The drug is now to be trialled with 500 Alzheimer's patients in nine European countries.

"Should this clinical trial be successful, nilvadipine would become the first Alzheimer's drug that not only reduces the symptoms of the disease but also acts on its causes. This could dramatically reduce Europe's costs for caring for patients with this neurodegenerative disease," says Anne Bφrjesson-Hanson, a researcher at Sahlgrenska Academy, University of Gothenburg, who is leading the Swedish participation in the study.

The patients in the study will be treated with nilvadipine or a placebo (inactive substance) for eighteen months. Patients who are already being treated with drugs to relieve the symptoms of Alzheimer's will continue to take them as before. Follow-up and check-ups will be carried out at the memory clinic at Sahlgrenska University Hospital.

"We will carry out repeated tests on the patients to see whether there are changes in memory and cognition during the trial period," says Anne Bφrjesson-Hanson.

This major European research collaboration is called NILVAD, and is being coordinated from Trinity College in Dublin, Ireland. Research teams in the UK, France, Netherlands, Greece, Hungary, Italy and Germany are taking part alongside Ireland and Sweden.

For further information about the project, see: www.nilvad.eu


Story Source:

The above story is based on materials provided by University of Gothenburg. Note: Materials may be edited for content and length.


Cite This Page:

University of Gothenburg. "Promising Alzheimer's drug trialled in large EU study." ScienceDaily. ScienceDaily, 9 December 2013. <www.sciencedaily.com/releases/2013/12/131209105022.htm>.
University of Gothenburg. (2013, December 9). Promising Alzheimer's drug trialled in large EU study. ScienceDaily. Retrieved July 28, 2014 from www.sciencedaily.com/releases/2013/12/131209105022.htm
University of Gothenburg. "Promising Alzheimer's drug trialled in large EU study." ScienceDaily. www.sciencedaily.com/releases/2013/12/131209105022.htm (accessed July 28, 2014).

Share This




More Mind & Brain News

Monday, July 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Losing Sleep Leaves You Vulnerable To 'False Memories'

Losing Sleep Leaves You Vulnerable To 'False Memories'

Newsy (July 27, 2014) — A new study shows sleep deprivation can make it harder for people to remember specific details of an event. Video provided by Newsy
Powered by NewsLook.com
University Quiz Implies Atheists Are Smarter Than Christians

University Quiz Implies Atheists Are Smarter Than Christians

Newsy (July 25, 2014) — An online quiz from a required course at Ohio State is making waves for suggesting atheists are inherently smarter than Christians. Video provided by Newsy
Powered by NewsLook.com
Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) — A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) — The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins